Wednesday, July 8, 2026

pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX

Viking Therapeutics

Viking Therapeutics clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
2012 Founded
60 Employees
Public company Type
VKTX · NYSE Ticker
Company details
Intelligence · Clinical Programs

Viking Therapeutics projects

1 ClinicalTrials.gov programs sponsored by Viking Therapeutics.

Viking Therapeutics has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. VK0214

    Viking Therapeutics

    Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Viking Therapeutics have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.